Experienced in Junctional Epidermolysis Bullosa

Dr. Amy S. Paller

Pediatric Faculty Foundation Inc
Chicago, IL
Experienced
in Junctional Epidermolysis Bullosa
Specialties:Pediatrics | Dermatology
OverviewInsuranceLocationsClinical Research

Overview

Amy Paller is a Pediatrics specialist and a Dermatologist in Chicago, Illinois. Mrs. Paller and is rated as an Experienced provider by MediFind in the treatment of Junctional Epidermolysis Bullosa. Her top areas of expertise are Atopic Dermatitis, Nonbullous Congenital Ichthyosiform Erythroderma, Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects, Molluscum Contagiosum, and Gastrostomy.

Her clinical research consists of co-authoring 425 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Junctional Epidermolysis Bullosa.

Specialties
Pediatrics
Dermatology
Licenses
Pediatrics in IL
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

PEDIATRIC FACULTY FOUNDATION INC
225 E Chicago Ave, Chicago, IL 60611
312-227-6415

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Early Phase 1
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Other
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Biological
Study Drug: Open Label Topical Beremagene Geperpavec (B-VEC)
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Enrollment Status: Completed
Publish Date: February 17, 2023
Intervention Type: Biological, Other
Study Drug: Topical Beremagene Geperpavec
Study Phase: Phase 3
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: RGN-137
Study Phase: Phase 2
A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU
A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Device
Genetic Analysis of Pediatric Psoriasis
Genetic Analysis of Pediatric Psoriasis
Enrollment Status: Completed
Publish Date: April 20, 2022
Intervention Type: Other
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments Sub-Study: Clinically Relevant Endpoints in Atopic Dermatitis in Children (CREAD-C)--Funded by Regeneron
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments Sub-Study: Clinically Relevant Endpoints in Atopic Dermatitis in Children (CREAD-C)--Funded by Regeneron
Enrollment Status: Completed
Publish Date: October 09, 2020
Intervention Type: Other
Study Phase: Not Applicable
Pre-SunBeam Pilot Study: Comparative Assessment of TEWL Measurements From AquaFlux vs. Handheld GPSkin Pro in Young Children With and Without AD
Pre-SunBeam Pilot Study: Comparative Assessment of TEWL Measurements From AquaFlux vs. Handheld GPSkin Pro in Young Children With and Without AD
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

425 Total Publications

Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Journal: Current medical research and opinion
Published: December 03, 2024
Similar Doctors
Expertise in
13
conditions
Dr. Kristin H. Lee
Dermatology
Expertise in
13
conditions
Dr. Kristin H. Lee
Dermatology

Northwestern Medicine Department Of Dermatology

676 N Saint Clair St, Suite 1600 Arkes Pavilion, 
Chicago, IL 
 (0.2 mi)
312-695-8106
Languages Spoken:
English, French, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kristin Lee is a Dermatologist in Chicago, Illinois. Dr. Lee and is rated as a Distinguished provider by MediFind in the treatment of Junctional Epidermolysis Bullosa. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Anaplastic Large Cell Lymphoma, and Lymphomatoid Papulosis. Dr. Lee is currently accepting new patients.

Expertise in
1
conditions
Dr. Anne E. Laumann
Dermatology
Expertise in
1
conditions
Dr. Anne E. Laumann
Dermatology
680 N Lake Shore Dr, Suite 1000, 
Chicago, IL 
 (0.3 mi)
312-695-9797
Languages Spoken:
English
See accepted insurances

Anne Laumann is a Dermatologist in Chicago, Illinois. Dr. Laumann and is rated as an Experienced provider by MediFind in the treatment of Junctional Epidermolysis Bullosa. Her top areas of expertise are Osteopoikilosis, Psoriasis, Squamous Cell Skin Carcinoma, and Dermatomyositis.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
View All 8 Elite Conditions
View All 13 Distinguished Conditions
View All 40 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile